Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Diabetes

Journal Scan / Research · July 15, 2023

Beta-Cell Function Is the Dominant Baseline Determinant of Type 2 Diabetes Remission in Response to Short-Term Insulin-Based Therapy

Diabetes, Obesity & Metabolism


Additional Info

Disclosure statements are available on the authors' profiles:

Diabetes, Obesity & Metabolism
Baseline determinants of remission of type 2 diabetes in response to short-term insulin-based therapy: The pivotal role of beta-cell function
Diabetes Obes Metab 2023 Jun 28;[EPub Ahead of Print], R Retnakaran, J Pu, A Emery, CK Kramer, B Zinman

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading